What does this research mean for the field?

Coumarin-based prodrugs have potential therapeutic applications across various diseases but remain largely confined to preclinical exploration due to challenges in clinical translation. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to assess the therapeutic potential of coumarin-based prodrugs and their preclinical status.

March 13, 2026PharmaceuticsOpen Access

Coumarin-Based Prodrugs: Therapeutic Promise or Still Confined to Preclinical Exploration?

View Full Paper

Ask AI

Bookmark

Authors

AAAtziri Corin Chavez Alvarez EMEmmanuel Moreau

Discussion

Member takes

Overview

This review evaluates coumarin-based prodrugs' therapeutic potential in various diseases, highlighting translational challenges.

Key Points

The aim is to assess the therapeutic potential of coumarin-based prodrugs and their preclinical status.
Review of coumarin scaffolds in prodrug design
Evaluation of activation strategies including enzymatic, pH, redox, and light-triggered methods
Analysis of preclinical studies across oncology, inflammation, infectious diseases, and cardiovascular disorders
Coumarin-based prodrugs show improved bioavailability and reduced off-target toxicity in preclinical models.
Real-time fluorescence monitoring is achieved through some prodrug designs.
Most prodrugs remain at the in vitro or small-animal model stage, with limited clinical translation.

Cite This Study

Alvarez et al. (2026) studied this question.

synapsesocial.com/papers/69b3acc502a1e69014cceb3e https://doi.org/10.3390/pharmaceutics18030341

View Full Paper

Ask AI

Bookmark

March 13, 2026PharmaceuticsOpen Access

Coumarin-Based Prodrugs: Therapeutic Promise or Still Confined to Preclinical Exploration?

View Full Paper

Ask AI

Bookmark

Authors

AAAtziri Corin Chavez Alvarez EMEmmanuel Moreau

Discussion

Member takes

Overview

This review evaluates coumarin-based prodrugs' therapeutic potential in various diseases, highlighting translational challenges.

Key Points

The aim is to assess the therapeutic potential of coumarin-based prodrugs and their preclinical status.
Review of coumarin scaffolds in prodrug design
Evaluation of activation strategies including enzymatic, pH, redox, and light-triggered methods
Analysis of preclinical studies across oncology, inflammation, infectious diseases, and cardiovascular disorders
Coumarin-based prodrugs show improved bioavailability and reduced off-target toxicity in preclinical models.
Real-time fluorescence monitoring is achieved through some prodrug designs.
Most prodrugs remain at the in vitro or small-animal model stage, with limited clinical translation.

Cite This Study

Alvarez et al. (2026) studied this question.

synapsesocial.com/papers/69b3acc502a1e69014cceb3e https://doi.org/10.3390/pharmaceutics18030341

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark